Multicell Techs Inc

0.000100.00Vol 1.00M1Y Perf -50.00%
Dec 7th, 2021 09:30
BID0.0000 ASK0.0000
Open0.0001 Previous Close0.0001
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.00 
Earnings Rating
Market Cap- 
Earnings Date
-
Alpha2.46 Standard Deviation14.16
Beta5.53 

Today's Price Range

0.00010.0001

52W Range

0.00010.0083

5 Year PE Ratio Range

-1.0000-1.8000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
0.00%
3 Months
-50.00%
6 Months
-91.67%
1 Year
-50.00%
3 Years
0.00%
5 Years
-50.00%
10 Years
0.00%

TickerPriceChg.Chg.%
MCET0.00010.00000.00
AAPL171.185.86003.54
GOOG2 960.7384.80002.95
MSFT334.928.73002.68
XOM62.270.69001.12
WFC50.251.44002.95
JNJ163.000.06000.04
FB322.814.94001.55
GE97.551.54001.60
JPM162.572.41001.50
Earnings HistoryEstimateReportedSurprise %
Q03 2015-0.00-
Q02 2015-0.00-
Q01 2005--0.05-
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.00M
Shares Outstanding0
Shares Float4.99B
Trades Count1
Dollar Volume100
Avg. Volume89.16M
Avg. Weekly Volume7.84M
Avg. Monthly Volume4.75M
Avg. Quarterly Volume8.17M
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Multicell Techs Inc

MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize and differentiate stem cells from human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.

CEO: W. Gerald Newmin

Telephone: +1 401 762-0045

Address: 68 Cumberland Street, Woonsocket 02895, RI, USA

Number of employees: 2

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

25%75%

Bearish Bullish

45%55%

Bearish Bullish

36%64%

News